Results of the Inclusion of New Medications in the Obligatory Health System Plan in Colombia, 2012-2013.

Background: The Colombian health care system has had a plan with limited benefits, but since 2012, 57 drugs have been added to this plan.

Objectives: The objective of this article was to describe the trends of utilization and costs of medications covered by the Agreement 029/2011 and compare them with those that were contained in the benefits plan.

Methods: This descriptive study involved a group of 3.

Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

This study describes the adverse drug reactions (ADRs) and their incidence in patients with rheumatoid arthritis who were treated in the Colombian health system. A retrospective cohort study was conducted using information from all patients who were diagnosed with rheumatoid arthritis and attended specialized health care centers in the cities of Bogotá, Cali, Manizales, Medellin, and Pereira between 1 December 2009 and 30 August 2013. The ADRs were obtained from medical records and the pharmacovigilance system registry and sorted by frequency and affected tissue according to World Health Organization Adverse Reaction Terminology (WHO-ART).